Niche oncology Amarantus focuses on neurology, regenerative medicine and orphan diseases with diagnostic and therapeutic assets that may pair with academic, government, and niche biotech funding channels. Sales opportunities exist in partnering for expanded clinical studies, licensing additional rights, or co-development agreements to accelerate Phase 2/2b programs such as ESS and eltoprazine.

Regenerative medicine angle Engineered Skin Substitute and related regenerative assets present a path for collaboration with hospitals and military programs (CRADA with US Army). There are potential sales opportunities in contract research, clinical trial services, and strategic partnerships to advance late-stage development and pivotal trials.

Diagnostics leverage Owned diagnostics like MSPrecise, LymPro Test, and NuroPro offer cross-portfolio selling opportunities to neurology and neurodegenerative clinics, labs, and reference centers. Potential revenue through licensing deals, service agreements, or bundled diagnostic packages with therapeutic programs.

Small company agility With a lean team and multi-asset portfolio, Amarantus can pursue fast-moving partnerships, co-development, and reverse integration deals with mid-stage biotechs seeking to augment their pipeline with neuroscience or orphan-disease assets.

Strategic partnerships Amarantus is positioned to engage with academic centers (e.g., Leipzig University), defense collaborators, and GBHC-aligned initiatives to unlock joint development funding, data-sharing agreements, and pilot programs that can translate into commercial licensing or milestone-based collaboration agreements.